Drugs / CALDARET
CALDARET
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00078013 | Apr 2003 → Aug 2004 | acute myocardial infarction | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00050076 | Aug 2002 → Aug 2003 | congestive heart failure | Takeda | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CALDARET | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106572 ↗ |
| Known as | CALDARET MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106572 ↗ |
| Known as | MCC-135 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00050076 ↗ |
| Modality | Small molecule | — CHEMBL2106572 ↗ |
| Route | Oral | “MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks” NCT00050076 ↗ |